HORSHOLM, Denmark, July 30, 2002 (PRIMEZONE) -- The release of the interim financial report, H1 2002 scheduled for August 22, 2002 has been moved to August 21, 2002. Furthermore, Pharmexa is planning an Extraordinary General Meeting on August 21, 2002 to elect Claus Braestrup new member of the Board of Directors. Pharmexa's Financial Calendar for the remainder of 2002 is as follows:
August 21, 2002 Release of interim financial report, H1 2002
August 21, 2002 Extraordinary General Meeting
November 21, 2002 Release of interim financial report, 3rd quarter 2002
Jakob Schmidt Chief Financial Officer
Note to editors:
Pharmexa A/S (CSE: PHARMX) is a leading company in the field oftherapeutic vaccines for the treatment of serious chronic diseases.Pharmexa's proprietary AutoVac(TM) pharmaccine technology platform isbroadly applicable, but the company has focused its resources on anumber of cancer forms and chronic inflammatory diseases. Pharmexa'sresearch and development programs are targeted towards breast cancer,asthma, bone degeneration, allergy and neurodegenerative diseases.The Pharmexa Group has entered into collaborative agreements withLexigen/Merck KGaA, Ferring, Schering-Plough, H. Lundbeck,NeuroSearch, GlaxoSmithKline, Zycos, Epimmune and AstraZeneca. TheGroup has 153 employees. More information on Pharmexa can be found onwww.pharmexa.com.
Please click on the link to view the pdf file: http://reports.huginonline.com/867972/106101.pdf